One hundred and four patients were included and whilst there was no statistically significant difference between the treatment and placebo groups, a subgroup analysis stratified on SLFN11 expression showed improved PFS and OS in patients receiving temozolomide and veliparib whose tumours express SLFN11 [58]. The gene discussed is SLFN11; the disease is neoplasm.